141 related articles for article (PubMed ID: 12684918)
41. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
42. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death.
Wyen C; Hoffmann C; Schmeisser N; Wöhrmann A; Qurishi N; Rockstroh J; Esser S; Rieke A; Ross B; Lorenzen T; Schmitz K; Stenzel W; Salzberger B; Fätkenheuer G
J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1263-8. PubMed ID: 15385733
[TBL] [Abstract][Full Text] [Related]
43. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.
Albrecht H; Hoffmann C; Degen O; Stoehr A; Plettenberg A; Mertenskötter T; Eggers C; Stellbrink HJ
AIDS; 1998 Jul; 12(10):1149-54. PubMed ID: 9677163
[TBL] [Abstract][Full Text] [Related]
44. [Focal presentation of progressive multifocal leukoencephalopathy: first manifestation of human immunodeficiency virus infection].
Martínez L; Cuesta J; Santos S; Tejero C
Neurologia; 2008 Oct; 23(8):532-5. PubMed ID: 18392989
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
46. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy.
Thurnher MM; Post MJ; Rieger A; Kleibl-Popov C; Loewe C; Schindler E
AJNR Am J Neuroradiol; 2001 May; 22(5):977-84. PubMed ID: 11337345
[TBL] [Abstract][Full Text] [Related]
47. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).
Antinori A; Cingolani A; Lorenzini P; Giancola ML; Uccella I; Bossolasco S; Grisetti S; Moretti F; Vigo B; Bongiovanni M; Del Grosso B; Arcidiacono MI; Fibbia GC; Mena M; Finazzi MG; Guaraldi G; Ammassari A; d'Arminio Monforte A; Cinque P; De Luca A;
J Neurovirol; 2003; 9 Suppl 1():47-53. PubMed ID: 12709872
[TBL] [Abstract][Full Text] [Related]
48. Vacuolar myelopathy and vacuolar cerebellar leukoencephalopathy: a late complication of AIDS after highly active antiretroviral therapy-induced immune reconstitution.
Aboulafia DM; Taylor L
AIDS Patient Care STDS; 2002 Dec; 16(12):579-84. PubMed ID: 12542931
[TBL] [Abstract][Full Text] [Related]
49. Follow-up magnetic resonance imaging findings in patients with progressive multifocal leukoencephalopathy: evaluation of long-term survivors under highly active antiretroviral therapy.
Sakai M; Inoue Y; Aoki S; Sirasaka T; Uehira T; Takahama S; Nagai H; Yutani K; Yoshikawa K; Nakamura H
Jpn J Radiol; 2009 Feb; 27(2):69-77. PubMed ID: 19373535
[TBL] [Abstract][Full Text] [Related]
50. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era.
Antinori A; Ammassari A; Giancola ML; Cingolani A; Grisetti S; Murri R; Alba L; Ciancio B; Soldani F; Larussa D; Ippolito G; De Luca A
J Neurovirol; 2001 Aug; 7(4):323-8. PubMed ID: 11517411
[TBL] [Abstract][Full Text] [Related]
51. Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era.
Jiang R; Song Z; Liu L; Mei X; Sun J; Qi T; Wang Z; Song W; Tang Y; Yang J; Xu S; Zhao B; Shen Y; Zhang R; Chen J
Front Cell Infect Microbiol; 2023; 13():1208155. PubMed ID: 38029233
[TBL] [Abstract][Full Text] [Related]
52. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.
Cinque P; Bossolasco S; Brambilla AM; Boschini A; Mussini C; Pierotti C; Campi A; Casari S; Bertelli D; Mena M; Lazzarin A
J Neurovirol; 2003; 9 Suppl 1():73-80. PubMed ID: 12709876
[TBL] [Abstract][Full Text] [Related]
53. [Progressive multifocal leucoencephalopathy in AIDS patients. Hepatotoxicity of HAART in patients with hepatitis B or C].
Blanco Barrios A; Zancada Díaz de Entre-Sotos F; Gutiérrez Vivas A; Calderón Mariño N
An Med Interna; 2005 Aug; 22(8):376-8. PubMed ID: 16351490
[TBL] [Abstract][Full Text] [Related]
54. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy.
Miralles P; Berenguer J; Lacruz C; Cosín J; López JC; Padilla B; Muñoz L; García-de-Viedma D
AIDS; 2001 Sep; 15(14):1900-2. PubMed ID: 11579261
[TBL] [Abstract][Full Text] [Related]
55. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.
Royal W; Dupont B; McGuire D; Chang L; Goodkin K; Ernst T; Post MJ; Fish D; Pailloux G; Poncelet H; Concha M; Apuzzo L; Singer E
J Neurovirol; 2003 Jun; 9(3):411-9. PubMed ID: 12775425
[TBL] [Abstract][Full Text] [Related]
56. Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy.
Dalla-Pozza P; Hentzien M; Allavena C; Doe de Maindreville A; Bouiller K; Valantin MA; Lafont E; Zaegel-Faucher O; Cheret A; Martin-Blondel G; Cotte L; Bani-Sadr F;
AIDS; 2022 Mar; 36(4):539-549. PubMed ID: 34873087
[TBL] [Abstract][Full Text] [Related]
57. Progressive multifocal leukoencephalopathy as an AIDS-defining condition in a patient with high CD4+ T-lymphocyte count.
Silva RO; Fabiano RC; Pedrosa MS; Lambertucci JR; Silva LC
Rev Soc Bras Med Trop; 2011; 44(1):119-21. PubMed ID: 21340424
[TBL] [Abstract][Full Text] [Related]
58. PML update.
Crit Path AIDS Proj; 1997; (No 32):31. PubMed ID: 11364441
[TBL] [Abstract][Full Text] [Related]
59. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS.
Geschwind MD; Skolasky RI; Royal WS; McArthur JC
J Neurovirol; 2001 Aug; 7(4):353-7. PubMed ID: 11517416
[TBL] [Abstract][Full Text] [Related]
60. [Progressive multifocal leukoencephalopathy in patients with AIDS. Hepatotoxicity of HAART therapy in patients with coinfection by HBV or HCV].
Blanco Barrios A; Gutiérrez Vivas A; Zancada Díaz de Entre-Sotos F; Calderón Mariño N
Rev Clin Esp; 2004 Apr; 204(4):238-40. PubMed ID: 15104941
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
